RESUMO
The results of the clinico-microbiological investigation of the levofloxacin efficacy in the treatment of 38 patients with respiratory infections or various pyo-inflammatory lesions are presented. The positive results were stated in 29 (76.3%) patients. No adverse reactions were observed.
Assuntos
Antibacterianos/uso terapêutico , Bronquite/tratamento farmacológico , Levofloxacino/uso terapêutico , Pneumopatias/tratamento farmacológico , Dermatopatias Bacterianas/tratamento farmacológico , Infecções dos Tecidos Moles/tratamento farmacológico , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Bronquite/microbiologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Levofloxacino/administração & dosagem , Levofloxacino/efeitos adversos , Pneumopatias/microbiologia , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/microbiologia , Índice de Gravidade de Doença , Dermatopatias Bacterianas/microbiologia , Infecções dos Tecidos Moles/microbiologia , Resultado do Tratamento , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologia , Adulto JovemAssuntos
Anti-Infecciosos/uso terapêutico , Broncopneumonia/tratamento farmacológico , Ciprofloxacina/uso terapêutico , Adulto , Idoso , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/farmacocinética , Broncopneumonia/metabolismo , Ciprofloxacina/administração & dosagem , Ciprofloxacina/farmacocinética , Esquema de Medicação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Comprimidos/uso terapêutico , Resultado do TratamentoRESUMO
Clinical and microbiological efficacy of Cifran OD (Ranbaxy, India), a formulation with prolonged action and extended release of ciprofloxacin was studied in 22 patients with bacteriuria and lingering diabetes mellitus. Ciprofloxacin was used in doses of 500 or 1000 mg orally once a day depending on the severity of the disease singns for 2-3 weeks as etiotropic therapy and only in 2 cases with severe pyelonephritis it was used intravenously drop-wise and orally simultaneously. Twenty eight microbial strains isolated from urea of the patients were tested. The main species of the isolates belonged to the family Enterobacteriaceae. Twenty five isolates (89.3%) were susceptible to ciprofloxacin and 3 isolates (10.7%) were resistant. The clinical efficacy of ciprofloxacin was 90.9%.
Assuntos
Complicações do Diabetes/tratamento farmacológico , Fluoroquinolonas/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Ciprofloxacina/análogos & derivados , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/uso terapêutico , Enterobacteriaceae/efeitos dos fármacos , Enterobacteriaceae/isolamento & purificação , Feminino , Fluoroquinolonas/administração & dosagem , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23). The drug was used orally in a dose of 1 g once a day. The patients were divided into 2 groups: group 1 included patients with aggravation of chronic bronchitis and group 2 included patients with bacterial pneumonia. The recovery was stated in 77.7% of the patients in group 1, the other 26.3% of the patients showed clinical improvement. In the patients with pneumonia (group 2) the recovery was recorded in 100% of the cases. No significant side effects were observed.
Assuntos
Antibacterianos/uso terapêutico , Bronquite Crônica/tratamento farmacológico , Ciprofloxacina/uso terapêutico , Pneumonia Bacteriana/tratamento farmacológico , Adulto , Idoso , Contagem de Colônia Microbiana , Infecções Comunitárias Adquiridas/tratamento farmacológico , Infecções Comunitárias Adquiridas/microbiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia Bacteriana/microbiologiaAssuntos
Antibacterianos/uso terapêutico , Bronquite Crônica/tratamento farmacológico , Carbapenêmicos/uso terapêutico , Pneumonia Bacteriana/tratamento farmacológico , Adulto , Idoso , Antibacterianos/farmacologia , Bronquite Crônica/microbiologia , Carbapenêmicos/administração & dosagem , Carbapenêmicos/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Cocos Gram-Positivos/efeitos dos fármacos , Humanos , Imipenem/farmacologia , Imipenem/uso terapêutico , Injeções Intramusculares , Injeções Intravenosas , Masculino , Meropeném , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Tienamicinas/farmacologia , Tienamicinas/uso terapêuticoRESUMO
Sensitivity of 505 strains of gram-negative and gram-positive microorganisms to II generation fluoroquinolones (ciprofloxacin, pefloxacin) was determined. Strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus with different level of sensitivity were selected. Pharmacokinetics of the drugs was investigated after their administration per os in one dose. The resulting indices were used for calculation of the following parameters--Cmax/MIC and AUC/MIC. These parameters may be used in evaluation of the drugs efficacy and for dosing corrections.
Assuntos
Anti-Infecciosos/farmacologia , Anti-Infecciosos/farmacocinética , Ciprofloxacina/farmacologia , Ciprofloxacina/farmacocinética , Pefloxacina/farmacologia , Pefloxacina/farmacocinética , Anti-Infecciosos/sangue , Anti-Infecciosos/uso terapêutico , Cromatografia Líquida de Alta Pressão , Ciprofloxacina/sangue , Ciprofloxacina/uso terapêutico , Escherichia coli/efeitos dos fármacos , Humanos , Klebsiella pneumoniae/efeitos dos fármacos , Testes de Sensibilidade Microbiana/estatística & dados numéricos , Pefloxacina/sangue , Pefloxacina/uso terapêutico , Pseudomonas aeruginosa/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacosRESUMO
AIM: To analyze clinical, bactericidal effectiveness and pharmacokinetics of wide-spectrum antibiotic netromycin (NM). MATERIALS AND METHODS: The trial entered 29 patients: 21 with bronchopulmonary diseases (pneumonia and chronic bronchitis), 5 with exacerbation of chronic pyelonephritis, 2 with infectious endocarditis and 1 with peritonsillar abscess. RESULTS: Microbiologically, most of the agents (80.36%) showed sensitivity to NM. Pharmacologically, NM persisted long in blood serum and sputum irrespective of the administration mode. Positive clinical dynamics after NM treatment was achieved in all the patients but one who had a peritonsillar abscess. CONCLUSION: NM is highly active against both gram-positive and gram-negative flora. Side effects are minimal.
Assuntos
Bronquite/tratamento farmacológico , Gentamicinas/uso terapêutico , Netilmicina/uso terapêutico , Pneumonia/tratamento farmacológico , Pielonefrite/tratamento farmacológico , Adulto , Idoso , Bactérias/efeitos dos fármacos , Endocardite Bacteriana/tratamento farmacológico , Feminino , Gentamicinas/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Netilmicina/farmacologia , Abscesso Peritonsilar/tratamento farmacológicoRESUMO
Antibiotic susceptibility of 279 strains of gram-positive and gram-negative isolates from patients with bronchopulmonary infections was tested. It was shown that the frequency of resistance to ampicillin and sulacillin amounted to 36.5 and 28.8 per cent respectively. The highest clinical efficacy of sulacillin was observed in the treatment of acute pneumonia (good and satisfactory results in 76.2 and 19 per cent of the cases respectively) and chronic nonobstructive bronchitis (good and satisfactory results in 80 and 16 per cent respectively). The clinical efficacy of sulacillin was somewhat lower in the treatment of chronic obstructive bronchitis (good and satisfactory results in 50 and 30 per cent of the cases respectively). In the treatment of chronic purulent bronchitis no clinical effect was detected in 30 per cent of the cases and in 70 per cent of the cases the results were satisfactory. The total frequency of adverse reactions to sulacillin amounted to 18.8 per cent.
Assuntos
Ampicilina/uso terapêutico , Bronquite/tratamento farmacológico , Quimioterapia Combinada/uso terapêutico , Pneumonia/tratamento farmacológico , Sulbactam/uso terapêutico , Doença Aguda , Ampicilina/efeitos adversos , Ampicilina/farmacocinética , Ampicilina/farmacologia , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Bronquite/sangue , Bronquite/microbiologia , Doença Crônica , Combinação de Medicamentos , Avaliação de Medicamentos , Quimioterapia Combinada/efeitos adversos , Quimioterapia Combinada/farmacocinética , Quimioterapia Combinada/farmacologia , Humanos , Testes de Sensibilidade Microbiana , Pneumonia/sangue , Pneumonia/microbiologia , Sulbactam/efeitos adversos , Sulbactam/farmacocinética , Sulbactam/farmacologiaRESUMO
The drug erik was used in 32 patients with chronic bronchitis and acute bacterial pneumonia. Out of 132 strains assessed for sensitivity, 94 (68.6%) were sensitive to the above antibiotic, the rest demonstrated moderate sensitivity or drug resistance. The dose 0.5 g persisted in the blood for up to 12 hours allowing its use three times in 24 hours. The response was achieved in 32 patients (72.18%).
Assuntos
Bronquite/tratamento farmacológico , Eritromicina/uso terapêutico , Pneumonia/tratamento farmacológico , Doença Aguda , Bronquite/microbiologia , Doença Crônica , Humanos , Testes de Sensibilidade Microbiana , Pneumonia/microbiologia , Resultado do TratamentoRESUMO
Rifametoprim (600 mg/day) was given to 64 patients with acute bacterial pneumonia, acute bronchitis and exacerbation of chronic bronchitis. 201 (83.4%) out of 241 isolates were sensitive to the action of the antibiotic. The treatment turned out effective in 84.4% of cases.
Assuntos
Bronquite/tratamento farmacológico , Pneumonia/tratamento farmacológico , Rifampina/uso terapêutico , Trimetoprima/uso terapêutico , Doença Aguda , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Bronquite/microbiologia , Cápsulas , Doença Crônica , Combinação de Medicamentos , Avaliação de Medicamentos , Humanos , Testes de Sensibilidade Microbiana , Pneumonia/microbiologia , Indução de Remissão , Escarro/microbiologiaRESUMO
Acute course and long-term regimens of depin-E administration were evaluated clinically and pharmacologically in 50 patients with chronic obstructive bronchitis (COB) and chronic cor pulmonale (CCP). The drug has three mechanisms of action: arteriolovenodilating, bronchodilating, direct pulmonary vascular. Therapeutic effect was achieved in 80% and 60% of COB and CCP patients, respectively. No response was demonstrated for patients with severe cardiac failure. Depin-E can be recommended for prophylaxis and treatment of CCP, to arrest hypertension crises in lesser circulation, to improve pulmonary circulation, central hemodynamics, exercise tolerance.